Fernández-González Felipe J, Cañigral Aránzazu, López-Caballo José L, Brizuela Aritza, Cobo Teresa, de Carlos Félix, Suazo Iván, Pérez-González Yurena, Vega Jose A
*Department of Orthodontics and Dentofacial Orthopedics, University of Oviedo, Oviedo, Spain,
*Department of Orthodontics and Dentofacial Orthopedics, University of Oviedo, Oviedo, Spain.
Eur J Orthod. 2016 Aug;38(4):379-85. doi: 10.1093/ejo/cjv056. Epub 2015 Aug 20.
Anchorage is one of the most challenging sides in orthodontics. The use of biological modulators that inhibit osteoclasts could be a solution to address these problems and provide new adjunctive approaches. The aim of this study was to assess the effectiveness of recombinant osteoprotegerin fusion protein (OPG-Fc) in orthodontic anchorage.
Two groups of male Sprague-Dawley rats were utilized. The animals in the experimental group received twice-weekly injections with high dose of OPG-Fc (5.0mg/kg) in mesial and distal mucosa of the first molars, and those in the control group received no drugs. Right first maxillary molars were mesialized using a calibrated nickel-titanium spring connected to an anterior mini-screw. Tooth movement was measured by two blinded observers using scanned and magnified stone casts. Receptor activator of nuclear factor κB (RANK), run-related transcription factor 2 (Runx2), type I collagen, vimentin, matrix metalloproteinases 2 and 9, S100 protein and the putative mechanoproteins acid-sensing ion channel (ASIC2) and transient receptor potential vainilloid 4 (TRPV4) were evaluated using immunohistochemistry.
OPG-Fc group showed an important decreased in mesial molar movement with only 52%, 31%, and 22% of the total mesial molar movement compared with control group at Days 7, 14, and 21, respectively (P < 0.001). RANK ligand and Runx2 positive cells were severely reduced after OPG-Fc treatment. Periodontal ligament architecture, cell arrangement, and immunohistochemical patter for vimentin, type I collagen and the mechanoproteins TRPV4 and ASIC2 were altered by tooth movement and all these parameters altered by the applied treatment.
OPG-Fc effectively inhibits osteoclastogenesis resulting in improved bone quantity and orthodontic anchorage. Based on present results, OPG-Fc could have clinical utility in preventing undesired tooth movements.
支抗是正畸治疗中最具挑战性的方面之一。使用抑制破骨细胞的生物调节剂可能是解决这些问题并提供新辅助方法的一种途径。本研究的目的是评估重组骨保护素融合蛋白（OPG-Fc）在正畸支抗中的有效性。
使用两组雄性Sprague-Dawley大鼠。实验组动物每周两次在第一磨牙近中和远中黏膜注射高剂量OPG-Fc（5.0mg/kg），对照组动物不注射药物。使用连接到前部微型螺钉的校准镍钛弹簧将右侧上颌第一磨牙近中移动。由两名不知情的观察者使用扫描和放大的石膏模型测量牙齿移动。使用免疫组织化学评估核因子κB受体激活剂（RANK）、与Run相关转录因子2（Runx2）、I型胶原蛋白、波形蛋白、基质金属蛋白酶2和9、S100蛋白以及假定的机械感受蛋白酸敏感离子通道（ASIC2）和瞬时受体电位香草酸受体4（TRPV4）。
OPG-Fc组近中磨牙移动明显减少，在第7天、14天和21天，与对照组相比，分别仅为总近中磨牙移动的52%、31%和22%（P<0.001）。OPG-Fc治疗后RANK配体和Runx2阳性细胞显著减少。牙齿移动改变了牙周膜结构、细胞排列以及波形蛋白、I型胶原蛋白和机械感受蛋白TRPV4和ASIC2的免疫组织化学模式，并通过应用治疗改变了所有这些参数。
OPG-Fc有效抑制破骨细胞生成，从而改善骨量和正畸支抗。基于目前的结果，OPG-Fc在预防不必要的牙齿移动方面可能具有临床应用价值。
